+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

Osteoporosis Drugs Market by Drug Class, Parathyroid Hormone Therapy, Calcitonin, Rank Ligand Inhibitors, and Others and Route of Administration: Global Opportunity Analysis and Industry Forecast, 2019-2026

  • ID: 5031411
  • Report
  • March 2020
  • Region: Global
  • 230 Pages
  • Allied Analytics LLP
1 of 5

FEATURED COMPANIES

  • Amgen Inc.
  • F. Hoffmann-La Roche AG
  • Pfizer Inc.
  • MORE

The global osteoporosis drugs market accounted for $7,657 million in 2018 and is expected to reach $10,479 million by 2026, registering a CAGR of 3.9% from 2019 to 2026.

Osteoporosis drugs are defined as therapeutic agents which are utilized in the treatment of osteoporosis. Furthermore, osteoporosis is a serious medical condition that is associated with the presence of fragile bones. In addition, these fragile bones are dense and prone to fractures. Moreover, the condition is caused due to the overproduction of hormone parathyroid and leads to limited mobility in patients suffering from the condition. Thus, this medical condition requires early diagnosis and medical treatment which includes the administration of various drugs such as bisphosphonates selective oestrogen inhibitors modulator (SERM), parathyroid hormone therapy, calcitonin, rank ligand inhibitors and others. In addition, these drugs are administered through different routes in the body such as oral route of administration, intravenous route of administration and others.

The major factor that contributes to the growth of the osteoporosis drugs market include a rise in The prevalence of osteoporosis. Furthermore, other factors that boost osteoporosis drugs market growth include a surge in the geriatric population across the globe and a rise in the adoption of a sedentary lifestyle worldwide. However, the side effects of osteoporosis drugs, and stringent regulatory environment and the time-consuming drug approval process hampers the growth of osteoporosis drugs market. Conversely, high growth potential in developing economies is expected to offer lucrative opportunities during the forecast period.

The osteoporosis drugs market size is studied on the basis of drug class, route of administration, and region to provide a detailed assessment of the market. On the basis of drug class, it is segmented into bisphosphonates, selective oestrogen inhibitors modulator (SERM), parathyroid hormone therapy, calcitonin, rank ligand inhibitors, and others. By route of administration, it is bifurcated into oral, injectable and others. Region wise, it is analyzed across North America (the U.S., Canada, and Mexico), Europe (Germany, France, the UK, Italy, Spain, and rest of Europe), Asia-Pacific (China, Japan, India, Australia, South Korea, and Rest of Asia-Pacific), and LAMEA (Brazil, South Africa, and Rest of LAMEA).

KEY BENEFITS FOR STAKEHOLDERS

  • This report entails a detailed quantitative analysis along with the current global osteoporosis treatment market trends from 2019 to 2026 to identify the prevailing opportunities along with the strategic assessments.
  • The market size and estimations are based on a comprehensive analysis of key developments in the industry.
  • A qualitative analysis based on innovative products facilitates strategic business planning.
  • The development strategies adopted by the key market players are enlisted to understand the competitive scenario of the market

Key Market Segments

By Drug Class

  • Bisphosphonates
  • Selective Estrogen Inhibitors Modulator (SERM)
  • Parathyroid Hormone Therapy
  • Calcitonin
  • Rank Ligand Inhibitors
  • Others

By Route of administration

  • Oral
  • Injectable
  • Others

By Region

  • North America
  • U.S.
  • Canada
  • Mexico
  • Europe
  • Germany
  • France
  • UK
  • Italy
  • Rest of Europe
  • Asia-Pacific
  • Japan
  • China
  • India
  • Rest of Asia-Pacific
  • LAMEA
  • Brazil
  • Saudi Arabia
  • South Africa
  • Rest of LAMEA

List of key players profiled in the report:

  • Amgen Inc.
  • F. Hoffmann-La Roche AG
  • Radius Health, Inc.
  • Merck & Co. Inc.
  • Novartis International AG (Sandoz)
  • Pfizer Inc.
  • Sun Pharmaceutical Industries Ltd.
  • Takeda Pharmaceutical Company Limited
  • Teva Pharmaceutical Industries Ltd

LIST OF OTHER PLAYERS IN THE VALUE CHAIN(These players are not profiled in the report. The same will be included on request)

  • GlaxoSmithKline plc
  • Novo Nordisk A/S
Note: Product cover images may vary from those shown
2 of 5

FEATURED COMPANIES

  • Amgen Inc.
  • F. Hoffmann-La Roche AG
  • Pfizer Inc.
  • MORE
CHAPTER 1: INTRODUCTION
1.1. Report description
1.2. KEY BENEFITS FOR STAKEHOLDERS
1.3. Key market segments
1.4. Research methodology
1.4.1. Secondary research
1.4.2. Primary research
1.4.3. Analyst tools and models

CHAPTER 2: EXECUTIVE SUMMARY
2.1. Key findings of the study
2.2. CXO perspective

CHAPTER 3: MARKET OVERVIEW
3.1. Market definition and scope
3.2. Top player positioning
3.2.1. Top investment pockets
3.3. Porter's five force analysis
3.4. Market dynamics
3.4.1. Drivers
3.4.1.1. Rise in The prevalence of osteoporosis
3.4.1.2. Rapid increase in aging population
3.4.1.3. Adoption of sedentary lifestyle
3.4.2. Restraints
3.4.2.1. Side effects of osteoporosis drugs
3.4.2.2. Stringent regulatory drug approval process
3.4.3. Opportunity
3.4.3.1. High growth prospects in emerging markets
3.4.4. Impact analyses

CHAPTER 4: OSTEOPOROSIS DRUGS MARKET, BY DRUG CLASS
4.1. Overview
4.1.1. Market size and forecast
4.2. Bisphosphonates
4.2.1. Key market trends, growth factors, and opportunities
4.2.2. Market size and forecast, by region
4.2.3. Market analysis, by country
4.3. Selective oestrogen inhibitors modulator
4.3.1. Key market trends, growth factors, and opportunities
4.3.2. Market size and forecast, by region
4.3.3. Market analysis, by country
4.4. Parathyroid hormone therapy
4.4.1. Key market trends, growth factors, and opportunities
4.4.2. Market size and forecast, by region
4.4.3. Market analysis, by country
4.5. Calcitonin
4.5.1. Key market trends, growth factors, and opportunities
4.5.2. Market size and forecast, by region
4.5.3. Market analysis, by country
4.6. Rank ligand inhibitors
4.6.1. Key market trends, growth factors, and opportunities
4.6.2. Market size and forecast, by region
4.6.3. Market analysis, by country
4.7. Others
4.7.1. Key market trends, growth factors, and opportunities
4.7.2. Market size and forecast, by region
4.7.3. Market analysis, by country

CHAPTER 5: OSTEOPOROSIS DRUGS MARKET, BY ROUTE OF ADMINISTRATION
5.1. Overview
5.1.1. Market size and forecast
5.2. Oral
5.2.1. Market size and forecast, by region
5.2.2. Market analysis, by country
5.3. Injectable
5.3.1. Market size and forecast, by region
5.3.2. Market analysis, by country
5.4. Others
5.4.1. Market size and forecast, by region
5.4.2. Market analysis, by country

CHAPTER 6: OSTEOPOROSIS DRUGS MARKET, BY REGION
6.1. Overview
6.1.1. Market size and forecast
6.2. North America
6.2.1. Key market trends and opportunities
6.2.2. North America osteoporosis drugs market, by country
6.2.2.1. U. S.
6.2.2.1.1. U. S. market size and forecast, by drug class
6.2.2.1.2. U. S. market size and forecast, by route of administration
6.2.2.2. Canada
6.2.2.2.1. Canada market size and forecast, by drug class
6.2.2.2.2. Canada market size and forecast, by route of administration
6.2.2.3. Mexico
6.2.2.3.1. Mexico market size and forecast, by drug class
6.2.2.3.2. Mexico market size and forecast, by route of administration
6.2.3. North America market size and forecast, by drug class
6.2.4. North America market size and forecast, by route of administration
6.3. Europe
6.3.1. Key market trends and opportunities
6.3.2. Europe osteoporosis drugs market, by country
6.3.2.1. Germany
6.3.2.1.1. Germany market size and forecast, by drug class
6.3.2.1.2. Germany market size and forecast, by route of administration
6.3.2.2. France
6.3.2.2.1. France market size and forecast, by drug class
6.3.2.2.2. France market size and forecast, by route of administration
6.3.2.3. UK
6.3.2.3.1. UK market size and forecast, by drug class
6.3.2.3.2. UK market size and forecast, by route of administration
6.3.2.4. Italy
6.3.2.4.1. Italy market size and forecast, by drug class
6.3.2.4.2. Italy market size and forecast, by route of administration
6.3.2.5. Spain
6.3.2.5.1. Spain market size and forecast, by drug class
6.3.2.5.2. Spain market size and forecast, by route of administration
6.3.2.6. Rest of Europe
6.3.2.6.1. Rest of Europe market size and forecast, by drug class
6.3.2.6.2. Rest of Europe market size and forecast, by route of administration
6.3.3. Europe market size and forecast, by drug class
6.3.4. Europe market size and forecast, by route of administration
6.4. Asia-Pacific
6.4.1. Key market trends and opportunities
6.4.2. Asia-Pacific osteoporosis drugs market, by country
6.4.2.1. Japan
6.4.2.1.1. Japan market size and forecast, by drug class
6.4.2.1.2. Japan market size and forecast, by route of administration
6.4.2.2. China
6.4.2.2.1. China market size and forecast, by drug class
6.4.2.2.2. China market size and forecast, by route of administration
6.4.2.3. Australia
6.4.2.3.1. Australia market size and forecast, by drug class
6.4.2.3.2. Australia market size and forecast, by route of administration
6.4.2.4. India
6.4.2.4.1. India market size and forecast, by drug class
6.4.2.4.2. India market size and forecast, by route of administration
6.4.2.5. South Korea
6.4.2.5.1. South Korea market size and forecast, by drug class
6.4.2.5.2. South Korea market size and forecast, by route of administration
6.4.2.6. Rest of Asia-Pacific
6.4.2.6.1. Rest of Asia-Pacific market size and forecast, by drug class
6.4.2.6.2. Rest of Asia-Pacific market size and forecast, by route of administration
6.4.3. Asia-Pacific market size and forecast, by drug class
6.4.4. Asia-Pacific market size and forecast, by route of administration
6.5. LAMEA
6.5.1. Key market trends and opportunities
6.5.2. LAMEA osteoporosis drugs market, by country
6.5.2.1. Brazil
6.5.2.1.1. Brazil market size and forecast, by drug class
6.5.2.1.2. Brazil market size and forecast, by route of administration
6.5.2.2. Saudi Arabia
6.5.2.2.1. Saudi Arabia market size and forecast, by drug class
6.5.2.2.2. Saudi Arabia market size and forecast, by route of administration
6.5.2.3. South Africa
6.5.2.3.1. South Africa market size and forecast, by drug class
6.5.2.3.2. South Africa market size and forecast, by route of administration
6.5.2.4. Rest of LAMEA
6.5.2.4.1. Rest of LAMEA market size and forecast, by drug class
6.5.2.4.2. Rest of LAMEA market size and forecast, by route of administration
6.5.3. LAMEA market size and forecast, by drug class
6.5.4. LAMEA market size and forecast, by route of administration

CHAPTER 7: COMPANY PROFILES
7.1. Amgen Inc.
7.1.1. Company overview
7.1.2. Company snapshot
7.1.3. Operating business segments
7.1.4. Product portfolio
7.1.5. Business performance
7.1.6. Key strategic moves and developments
7.2. Eli Lilly and Company
7.2.1. Company overview
7.2.2. Company snapshot
7.2.3. Operating business segments
7.2.4. Product portfolio
7.2.5. Business performance
7.3. F. HOFFMANN-LA ROCHE LTD.
7.3.1. Company overview
7.3.2. Company snapshot
7.3.3. Operating business segments
7.3.4. Product portfolio
7.3.5. Business performance
7.4. Radius Health, Inc.
7.4.1. Company overview
7.4.2. Company snapshot
7.4.3. Operating business segments
7.4.4. Product portfolio
7.4.5. Business performance
7.5. Merck & Co. Inc.
7.5.1. Company overview
7.5.2. Company snapshot
7.5.3. Operating business segments
7.5.4. Product portfolio
7.5.5. Business performance
7.6. Novartis International AG (Sandoz)
7.6.1. Company overview
7.6.2. Company snapshot
7.6.3. Operating business segments
7.6.4. Product portfolio
7.6.5. Business performance
7.7. Pfizer Inc.
7.7.1. Company overview
7.7.2. Company snapshot
7.7.3. Operating business segments
7.7.4. Product portfolio
7.7.5. Business performance
7.8. Sun Pharmaceutical Industries Ltd.
7.8.1. Company overview
7.8.2. Company snapshot
7.8.3. Operating business segments
7.8.4. Product portfolio
7.8.5. Business performance
7.9. Takeda Pharmaceutical Company Limited
7.9.1. Company overview
7.9.2. Company snapshot
7.9.3. Operating business segments
7.9.4. Product portfolio
7.9.5. Business performance
7.10. Teva Pharmaceutical Industries Ltd.
7.10.1. Company overview
7.10.2. Company snapshot
7.10.3. Operating business segments
7.10.4. Product portfolio
7.10.5. Business performance
7.10.6. Key strategic moves and developments
Note: Product cover images may vary from those shown
3 of 5

FEATURED COMPANIES

  • Amgen Inc.
  • F. Hoffmann-La Roche AG
  • Pfizer Inc.
  • MORE

According to this report titled, 'Osteoporosis Drugs Market by Drug Class, and Route of Administration: Global Opportunity Analysis and Industry Forecast, 2019-2026,' the global osteoporosis drugs market size was valued at $8 billion in 2018 and is expected to reach $10 billion by 2026, registering a CAGR of 3.9% from 2019 to 2026.

Osteoporosis is a medical condition that involves the weakening of the bones. This medical condition is caused due to the overexpression of the parathyroid hormone. Moreover, weak bones are porous and susceptible to serious fractures. Therefore, osteoporosis has a significant impact on the quality of life of patients such as the condition that leads to limited mobility. Thus, this medical condition requires treatment which includes the administration of drugs such as bisphosphonates selective estrogen inhibitors modulator (SERM), parathyroid hormone therapy, calcitonin, rank ligand inhibitors, and others. Furthermore, these drugs are administered through different routes in the body. For instance, some osteoporosis drugs are administered through the oral route whereas others are administered through the intravenous route.

The major factor that contributes toward the growth of the global osteoporosis drug market includes a rise in The prevalence of osteoporosis. Furthermore, other factors that boost osteoporosis drug market growth include a surge in the geriatric population across the globe and a rise in the adoption of a sedentary lifestyle worldwide. However, the side effects of osteoporosis drugs, and the time-consuming drug approval process restrain the growth of the global osteoporosis drugs market. Conversely, high growth potential in developing economies is expected to offer lucrative opportunities during the forecast period.

The osteoporosis drugs market size is studied on the basis of drug class, route of administration, and region to provide a detailed assessment of the market. By drug class, it is segmented into bisphosphonates, selective estrogen inhibitors modulator (SERM), parathyroid hormone therapy, calcitonin, rank ligand inhibitors, and others. Depending on the route of administration, it is fragmented into oral, injectable and others. Region wise, it is analyzed across North America (the U.S., Canada, and Mexico), Europe (Germany, France, the UK, Italy, Spain, and Rest of Europe), Asia-Pacific (China, Japan, India, Australia, South Korea, and Rest of Asia-Pacific), and LAMEA (Brazil, South Africa, and Rest of LAMEA).

By drug class, the bisphosphonates segment acquired the major share of the osteoporosis drugs market in 2018 owing to an increase in investment in R&D of advanced novel bisphosphonates drugs by major players. However, rank ligand inhibitors segment is expected to exhibit the fastest growth rate during the forecast period owing to the fact that these drugs are used to treat bone metastasis by acting as a chemoattractant to bone for tumor cells that express its receptor, RANK. Thus, the inhibition of the RANKL-RANK pathway acts as an ideal treatment for bone metastasis which makes them a preferred choice of drug.

By route of administration, the oral segment acquired for the major share of the osteoporosis drugs market owing to a large number of osteoporosis medications that are available as oral drugs in the market. However, the injectable segment is expected to grow at the fastest CAGR during the forecast period owing to factors such as a rise in need for drugs that exhibit enhanced bioavailability, and act rapidly.

By region, North America accounted for the major osteoporosis drugs market share in 2018 and is expected to continue this trend, owing to the easy availability of osteoporosis drugs. Moreover, a surge in the incidence of osteoporosis is another major reason that contributes to the growth of this market. On the other side, Asia-Pacific is estimated to register the fastest growth during the forecast period attributed to the increase in awareness regarding the use of osteoporosis drugs for the treatment of osteoporosis. Moreover, the constantly evolving life science industry drives the growth of the market in developing economies such as India, China, and Malaysia.

According to Onkar Sumant, Manager, Healthcare, “The demand for osteoporosis drugs is on a rise, owing to surge in the incidence of osteoporosis globally. Furthermore, a rise in healthcare expenditure leads to the easy availability of osteoporosis drugs, which fuels market growth.”

KEY FINDINGS OF THE STUDY

  •     Bisphosphonates occupied more than one-third share of the global osteoporosis drugs market in 2018.
  •     The RANK ligand inhibitors segment is anticipated to grow with the highest CAGR throughout the forecast period.
  •     The oral segment in drug class accounted for more than half the share of the market in 2018.
  •     Asia-Pacific is anticipated to grow at the highest rate during the analysis period, followed by LAMEA
Note: Product cover images may vary from those shown
4 of 5
  • Amgen Inc.
  • F. Hoffmann-La Roche AG
  • Radius Health Inc. Merck & Co. Inc.
  • Novartis International AG (Sandoz)
  • Pfizer Inc.
  • Sun Pharmaceutical Industries Ltd.
  • Takeda Pharmaceutical Company Limited
  • Teva Pharmaceutical Industries Ltd
Note: Product cover images may vary from those shown
5 of 5

The analyst offers exhaustive research and analysis based on a wide variety of factual inputs, which largely include interviews with industry participants, reliable statistics, and regional intelligence. The in-house industry experts play an instrumental role in designing analytic tools and models, tailored to the requirements of a particular industry segment. The primary research efforts include reaching out participants through mail, tele-conversations, referrals, professional networks, and face-to-face interactions.

They are also in professional corporate relations with various companies that allow them greater flexibility for reaching out to industry participants and commentators for interviews and discussions.

They also refer to a broad array of industry sources for their secondary research, which typically include; however, not limited to:

  • Company SEC filings, annual reports, company websites, broker & financial reports, and investor presentations for competitive scenario and shape of the industry
  • Scientific and technical writings for product information and related preemptions
  • Regional government and statistical databases for macro analysis
  • Authentic news articles and other related releases for market evaluation
  • Internal and external proprietary databases, key market indicators, and relevant press releases for market estimates and forecast

Furthermore, the accuracy of the data will be analyzed and validated by conducting additional primaries with various industry experts and KOLs. They also provide robust post-sales support to clients.

Loading
LOADING...

Adroll
adroll